CN105661499A - 一种清血脂预防心脑血管疾病的功能食品及制备方法 - Google Patents
一种清血脂预防心脑血管疾病的功能食品及制备方法 Download PDFInfo
- Publication number
- CN105661499A CN105661499A CN201610009839.0A CN201610009839A CN105661499A CN 105661499 A CN105661499 A CN 105661499A CN 201610009839 A CN201610009839 A CN 201610009839A CN 105661499 A CN105661499 A CN 105661499A
- Authority
- CN
- China
- Prior art keywords
- blood
- fat
- functional food
- oligopeptide powder
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 21
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 20
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 16
- 235000013376 functional food Nutrition 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 22
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 16
- 244000068988 Glycine max Species 0.000 claims abstract description 10
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 10
- 102000008186 Collagen Human genes 0.000 claims abstract description 9
- 108010035532 Collagen Proteins 0.000 claims abstract description 9
- 240000006240 Linum usitatissimum Species 0.000 claims abstract description 9
- 235000004431 Linum usitatissimum Nutrition 0.000 claims abstract description 9
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 9
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 9
- 240000006365 Vitis vinifera Species 0.000 claims abstract description 9
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 9
- 240000008042 Zea mays Species 0.000 claims abstract description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 9
- 229920001436 collagen Polymers 0.000 claims abstract description 9
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 241000237502 Ostreidae Species 0.000 claims abstract description 8
- 235000020636 oyster Nutrition 0.000 claims abstract description 8
- 229920002752 Konjac Polymers 0.000 claims abstract description 7
- 240000004922 Vigna radiata Species 0.000 claims abstract description 7
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 7
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 7
- 239000000252 konjac Substances 0.000 claims abstract description 6
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 19
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 10
- 241000219784 Sophora Species 0.000 claims description 9
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 7
- 229940010454 licorice Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 6
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 6
- 235000009973 maize Nutrition 0.000 claims description 6
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 5
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 5
- 229920002581 Glucomannan Polymers 0.000 claims description 5
- 229940046240 glucomannan Drugs 0.000 claims description 5
- 235000010485 konjac Nutrition 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 235000021028 berry Nutrition 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 238000013035 low temperature curing Methods 0.000 claims description 2
- 238000001723 curing Methods 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 8
- 230000036772 blood pressure Effects 0.000 abstract description 7
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 abstract description 3
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 abstract description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract description 3
- 235000005822 corn Nutrition 0.000 abstract description 3
- 235000004634 cranberry Nutrition 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 239000003053 toxin Substances 0.000 abstract description 2
- 231100000765 toxin Toxicity 0.000 abstract description 2
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 abstract 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 abstract 1
- 240000001717 Vaccinium macrocarpon Species 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 abstract 1
- 235000019823 konjac gum Nutrition 0.000 abstract 1
- 229940051810 licorice root extract Drugs 0.000 abstract 1
- 235000020725 licorice root extract Nutrition 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 18
- 235000012000 cholesterol Nutrition 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000202807 Glycyrrhiza Species 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 230000003516 hyperlipidaemic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 244000291414 Vaccinium oxycoccus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005213 imbibition Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于食品生产技术领域,具体涉及一种清血脂预防心脑血管疾病的功能食品及制备方法。本发明所述功能食品的配方及配比为:槐米5%-30%、亚麻籽15%-30%、葡萄籽10%-25%、魔芋胶5%-10%、甘草提取物5%-15%、蔓越莓3%-12%、大豆低聚肽粉5%-15%、玉米低聚肽粉5%-15%、胶原蛋白肽粉7%-15%、绿豆低聚肽粉5%-10%、牡蛎低聚肽粉5%-10%。本发明所述功能食品不仅可以减少血管中脂质的形成,还能清除血管内壁已经形成的垃圾、毒素和斑块,同时软化血管,降低血压,保护心脑血管,防治各类心脑血管疾病。
Description
技术领域
本发明属于食品生产技术领域,具体涉及一种清血脂预防心脑血管疾病的功能食品及制备方法。
背景技术
血液中的脂类物质统称为血脂,血脂其实是人体中一种很重要的物质,具有多种生理功能,它们在血液中与不同的蛋白质结合在一起,以“脂蛋白”的形式存在。血浆的脂类包括胆固醇、甘油三酯、磷脂和非游离脂肪酸等,但是血脂不能超过一定的范围,血脂过多,容易造成“血稠”,在血管壁上沉积,逐渐形成小斑块,这些“斑块”增多、增大后会逐渐堵塞血管,使得血流变慢,严重时血流中断,这种情况发生在心脏,会引起冠心病,发生在脑部会引起中风,发生在眼底血管会导致视力下降、失明,发生在肾脏会引起肾动脉硬化,肾功能衰竭,发生在下肢会出现肢体坏死、溃烂等,另外还可能会引发高血压、胆结石、胰腺炎,加重肝炎、导致男性性功能障碍、老年痴呆等疾病,而最新的研究表明,高血脂可能还与癌症的发生有关。
目前我国人群血脂异常的发生率呈现上升趋势,虽然目前为止患病率尚低于西方国家,但是随着社会经济的发展,人民的生活水平不断提高,生活方式不断改变,人群的平均胆固醇水平也在逐步升高,且已经达到了较高的水平,在目前的经济转型阶段,高血脂的防治面临挑战。
高血脂分为原发性和继发性,前者与生活环境和家族遗传有关,后者由糖尿病、甲状腺功能低下、肥胖症、胰腺症等疾病引起的,对高血脂症早期预防具有重要意义,特别是具有遗传倾向的高血脂患者,药物治疗无明显的改善,需要通过合理的饮食来改善。
发明内容
本发明的目的在于提供一种安全便捷,可以长期服用的功能食品及其制备方法,帮助清除血脂,预防及辅助治疗心脑血管疾病。本发明采用天然食物材料,制备成安全无毒,可以长期服用以达到清血脂,预防及辅助治疗心脑血管疾病的功能食品。
本发明所述清血脂预防心脑血管疾病的功能食品,其配方由以下成分组成:槐米、亚麻籽、葡萄籽、魔芋胶、甘草提取物、蔓越莓、大豆低聚肽粉、玉米肽粉、胶原蛋白肽粉、绿豆低聚肽粉、牡蛎低聚肽粉。
各成分所占的重量比例为:槐米5%-30%、亚麻籽15%-30%、葡萄籽10%-25%、魔芋胶5%-10%、甘草提取物5%-15%、蔓越莓3%-12%、大豆低聚肽粉5%-15%、玉米低聚肽粉5%-15%、胶原蛋白肽粉7%-15%、绿豆低聚肽粉5%-10%、牡蛎低聚肽粉5%-10%。
槐米、葡萄籽由安徽省亳州市滕王药业提供;亚麻籽由杭州天龙健康产品有限公司提供;大豆低聚肽粉、玉米低聚肽粉、胶原蛋白肽粉、绿豆低聚肽粉、牡蛎低聚肽粉由山东中食都庆生物科技有限公司提供;甘草提取物由西安百川生物工程有限公司提供。
下面结合原料对本发明做进一步说明:
槐米:槐米为含苞待放的槐花的花蕾,含有较多的芦丁、维生素A、维生素B,这些成分具有明显的软化血管的作用,能降低毛细血管的通透性和脆性,可以增加毛细血管的抵抗力,对高血压病患者有阻止血管壁破裂的功效,还有扩张冠脉血管、改善心肌循环、降血压的功效。
亚麻籽:亚麻籽含有丰富的人体必需脂肪酸ω-3脂肪酸,可降低血清中的胆固醇和甘油三脂、分解脂肪、升高对人体有益的高密度蛋白,具有调节血脂的保健作用。对ω-3脂肪酸的研究始于爱斯基摩人与西欧人相比心肌梗塞、血栓、高血压等心脑血管疾病的发病率非常低这一现象的发现,原因即在于爱斯基摩人大量食用海产鱼类,我国的流行病学调查也发现,生活在沿海地区经常食用海产品的人群,心脑血管疾病的患病率较低,其原因就在于海洋鱼类中含有丰富的ω-3不饱和脂肪酸。
葡萄籽粉:葡萄籽含有丰富的花青素,具有抗氧化、抗过敏、延缓皮肤衰老等功效,并可提高高密度脂蛋白的比例,降低坏胆固醇-低密度脂蛋白胆固醇的水平,可防止、对抗延缓血管硬化,保护心脑血管,预防脑出血、脑血栓、脑梗、冠心病等疾病的发生。
本发明以以上三种原料为主要成分,有调节血脂、软化血管、降血压、保护心脑血管的作用。
低聚肽是由10个以下氨基酸组成的小分子肽,分子量远远小于蛋白质,通过肠道专门的转运通道吸收,具有多种保健功能,因此与蛋白质和氨基酸相比,吸收更快,生理功效更高。低聚肽可以促使粪便排泄,降低血清胆固醇浓度,使甾醇排泄增加,使肝脏高胆固醇浓度下降,对治疗原发性高血压有一定的功效,还能抑制脂肪的积蓄,抑制有害菌,排出毒素,促进其对食物营养的消化吸收,以提高人体对补充的营养素的吸收。
大豆低聚肽:大豆低聚肽能通过降低血清总胆固醇、降低三油甘脂、降低低密度脂蛋白胆固醇,有效调节血脂水平,还能增加褐色脂肪中线粒体的活性,促进脂肪代谢,增加去甲肾上腺素的转化率,减少对脂肪酶的抑制从而促进脂肪代谢,同时大豆低聚肽还具有很好的降压效果,还可以簇集小肠吸收功能的改善、增强机体的免疫力。
玉米低聚肽:玉米低聚肽可以降低胆固醇、增进体内胆固醇的代谢,增加粪甾醇的排泄功能,起到清除血脂的作用。还可以按捺血管紧张素转换酶的作用,降低血压,同时还具有抗疲劳、保肝、提高机体抵抗力等功能。
胶原蛋白肽:胶原蛋白肽可以降低血甘油三酯和胆固醇,并可增高体内一些缺乏的必必需微量元素,还有加速血红蛋白和红细胞生成的功效,有利于血液循环的改善,对冠心病、缺血性脑部疾病有改善作用。
绿豆低聚肽:绿豆多肽中含有多种氨基酸,还含有多种维生素及微量元素,以及鞣酸、生物碱、植物甾醇、黄酮等生物活性物质,动物实验表明,绿豆多肽具有明显的降低血液胆固醇的作用。
牡蛎蛋白肽:牡蛎肽中富含牛磺酸,牛磺酸能促进分解肝脏中的胆固醇,增加排泄,降低血液中的胆固醇含量,对于因淤血而产生的动脉粥样硬化以及可能引发的狭心症、心肌梗塞、脑梗塞等有很好的预防作用。
本发明以大豆低聚肽粉、玉米低聚肽粉、胶原蛋白肽粉、绿豆低聚肽粉、牡蛎蛋白肽粉为辅料,增强槐米、亚麻籽、葡萄籽的清血脂、软化血管、保护心脑血管的作用。
魔芋所含的葡萄糖甘露聚糖是一种半纤维素,吸水性极强,吸水膨胀后可使体积增长80倍左右,延缓了胃排空和食物在肠道内的消化和吸收,不仅是降低血脂、抗脂肪、降血糖、通利大便的佳品,也是对抗动脉粥样硬化的妙品。甘草性平味甘,对正常人的脂质代谢无影响,大多数患者服用甘草酸(甘草甜素)后胆固醇可以下降。小剂量甘草甜素可使实验性动脉粥样硬化的家兔血清胆固醇降低,减轻病灶并阻止大动脉及冠状动脉病灶的进展,甘草提取物除甘草可以有效对抗动脉硬化外,还具有娇味,改善口感的作用。蔓越莓中含有的单不饱和脂肪酸和生育三烯醇(酚),可避免低密度脂蛋白胆固醇氧化,它还含有另一种抗氧化心尖兵—浓缩单宁酸,可起到保护心脑血管健康的作用。
本发明以魔芋胶、甘草提取物、蔓越莓为辅佐材料,不仅具有保护心脑血管作用还可以改善产品风味。
与现有技术相比,本发明的有益效果是:本发明所述清血脂预防心脑血管疾病的功能食品不仅可以减少血管中脂质的形成,还能清除血管内壁已经形成的垃圾、毒素和斑块,同时软化血管,降低血压,保护心脑血管,防治各类心脑血管疾病。
具体实施方式
实施例1一种清血脂预防高血脂疾病的功能食品的制备方法:
一种清血脂预防高血脂疾病的功能食品,其配方原料及所占重量比例为:槐米5%-30%、亚麻籽15%-30%、葡萄籽10%-25%、魔芋胶5%-10%、甘草提取物5%-15%、蔓越莓3%-12%、大豆低聚肽粉5%-15%、玉米低聚肽粉5%-15%、胶原蛋白肽粉7%-15%、绿豆低聚肽粉5%-10%、牡蛎低聚肽粉5%-10%。
本发明的制作工艺为:
(1)低温烘焙:本配方选用80°~90°低温烘焙,确保营养成分不流失;
(2)超细粉碎:食材全部研成超细粉末,便于吸收;
(3)混合、均质:按配方比例将各成分混合、均质,包装。
实施例2
清血脂预防高血脂疾病功能食品的人群功效观察实验:
1、实验对象:
实验分为50-60岁、60-70岁、70-80岁3个年龄组,每组选取高血压、高血脂、动脉粥样硬化等心脑血管疾病患者30人,每个实验组选同样患有心脑血管疾病,病情相似,且生活环境、水平、习惯也相似的30人作为对照组。
2、实验方法:
按本发明配方制备的功能食品,分别给3个年龄段的实验组服用,一日2次,每次1袋,对照组正常饮食。实验时间为30天,分别在实验开始时、实验中期、实验末期对实验组及对照组进行血压、血脂(总胆固醇、三油甘脂、高密度脂蛋白、低密度脂蛋白)的体征检查,记录并比较检查结果。
3、效果评价:
++:表示经血压、血脂(总胆固醇、三油甘脂、高密度脂蛋白、低密度脂蛋白)检查,身体体征基本恢复正常,或保持在平稳状态。
+:表示经血压、血脂(总胆固醇、三油甘脂、高密度脂蛋白、低密度脂蛋白)检查,身体体征有所好转,但还未恢复正常。
-:表示经血压、血脂(总胆固醇、三油甘脂、高密度脂蛋白、低密度脂蛋白)检查,身体体征没有好转。
4、实验结果:
表150-60岁组功效观察结果
表260-70岁组功效观察结果
表370-80岁组功效观察结果
由表1、2、3可知,实验组高血压、高血脂的总改善率在70%以上,50-60岁组达到90%,与对照组相比总改善率有大幅度提高,且差异具有高度显著性(p<0.01),说明本发明具有良好的清血脂、降血压,预防心脑血管疾病的作用,同时本发明还可以在制备清血脂、降血压、预防心脑血管疾病的保健食品中应用。
Claims (2)
1.一种清血脂预防心脑血管疾病的的功能食品,其配方原料及所占重量比例为:槐米5%-30%、亚麻籽15%-30%、葡萄籽10%-25%、魔芋胶5%-10%、甘草提取物5%-15%、蔓越莓3%-12%、大豆低聚肽粉5%-15%、玉米低聚肽粉5%-15%、胶原蛋白肽粉7%-15%、绿豆低聚肽粉5%-10%、牡蛎低聚肽粉5%-10。
2.根据权利要求1所述清血脂预防心脑血管疾病功能食品的制备方法,其特征是由以下步骤构成:
(1)低温烘焙:将权利要求1所述配方原料用80°~90°低温烘焙;
(2)超细粉碎:将烘焙后的食材全部研成超细粉末;
(3)混合、均质:按权利要求1所述配方比例将各成分混合、均质,包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610009839.0A CN105661499A (zh) | 2016-01-07 | 2016-01-07 | 一种清血脂预防心脑血管疾病的功能食品及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610009839.0A CN105661499A (zh) | 2016-01-07 | 2016-01-07 | 一种清血脂预防心脑血管疾病的功能食品及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105661499A true CN105661499A (zh) | 2016-06-15 |
Family
ID=56299417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610009839.0A Pending CN105661499A (zh) | 2016-01-07 | 2016-01-07 | 一种清血脂预防心脑血管疾病的功能食品及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105661499A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106689948A (zh) * | 2016-11-30 | 2017-05-24 | 河北爱怡尚饮品有限公司 | 一种胶原蛋白复合亚麻酸饮料及其制备方法 |
CN106819967A (zh) * | 2016-12-23 | 2017-06-13 | 南京贝杉国际贸易有限公司 | 一种增强免疫力的人参黄精复合精粉及制备方法和应用 |
CN107156859A (zh) * | 2017-05-09 | 2017-09-15 | 西安美格森生物科技有限公司 | 一种供心脑血管病患者食用的含短肽食品 |
CN109224059A (zh) * | 2018-10-26 | 2019-01-18 | 湛江市通灵医学生物工程有限公司 | 复方制剂及其制备方法 |
CN110338326A (zh) * | 2019-07-10 | 2019-10-18 | 中慈保健品科技开发有限公司 | 辅助治疗心脑血管的大豆肽复配固体饮料及其制备方法和应用 |
CN111195308A (zh) * | 2020-02-26 | 2020-05-26 | 江苏食品药品职业技术学院 | 一种降压降脂复方制剂及其制备方法 |
CN112690386A (zh) * | 2020-12-05 | 2021-04-23 | 上海同济生物制品有限公司 | 一种具有抗氧化及抑菌作用并能增强心脑血管及人体免疫功能的食疗组方 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101715913A (zh) * | 2008-12-02 | 2010-06-02 | 天津天狮生物发展有限公司 | 一种活力康胶囊及其生产制作工艺 |
CN104839680A (zh) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 心血管疾病医学配方食品 |
CN104857034A (zh) * | 2015-04-14 | 2015-08-26 | 南京贝杉国际贸易有限公司 | 一种防治心脑血管疾病的功能食品及其制备方法 |
CN105124576A (zh) * | 2015-08-21 | 2015-12-09 | 刘涛 | 一种辅助降血糖的保健食品制备方法 |
-
2016
- 2016-01-07 CN CN201610009839.0A patent/CN105661499A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101715913A (zh) * | 2008-12-02 | 2010-06-02 | 天津天狮生物发展有限公司 | 一种活力康胶囊及其生产制作工艺 |
CN104839680A (zh) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 心血管疾病医学配方食品 |
CN104857034A (zh) * | 2015-04-14 | 2015-08-26 | 南京贝杉国际贸易有限公司 | 一种防治心脑血管疾病的功能食品及其制备方法 |
CN105124576A (zh) * | 2015-08-21 | 2015-12-09 | 刘涛 | 一种辅助降血糖的保健食品制备方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106689948A (zh) * | 2016-11-30 | 2017-05-24 | 河北爱怡尚饮品有限公司 | 一种胶原蛋白复合亚麻酸饮料及其制备方法 |
CN106689948B (zh) * | 2016-11-30 | 2021-04-09 | 河北爱怡尚饮品有限公司 | 一种胶原蛋白复合亚麻酸饮料及其制备方法 |
CN106819967A (zh) * | 2016-12-23 | 2017-06-13 | 南京贝杉国际贸易有限公司 | 一种增强免疫力的人参黄精复合精粉及制备方法和应用 |
CN107156859A (zh) * | 2017-05-09 | 2017-09-15 | 西安美格森生物科技有限公司 | 一种供心脑血管病患者食用的含短肽食品 |
CN109224059A (zh) * | 2018-10-26 | 2019-01-18 | 湛江市通灵医学生物工程有限公司 | 复方制剂及其制备方法 |
CN110338326A (zh) * | 2019-07-10 | 2019-10-18 | 中慈保健品科技开发有限公司 | 辅助治疗心脑血管的大豆肽复配固体饮料及其制备方法和应用 |
CN111195308A (zh) * | 2020-02-26 | 2020-05-26 | 江苏食品药品职业技术学院 | 一种降压降脂复方制剂及其制备方法 |
CN112690386A (zh) * | 2020-12-05 | 2021-04-23 | 上海同济生物制品有限公司 | 一种具有抗氧化及抑菌作用并能增强心脑血管及人体免疫功能的食疗组方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105661499A (zh) | 一种清血脂预防心脑血管疾病的功能食品及制备方法 | |
CN104312895B (zh) | 一种苦荞醋及其制备方法 | |
CN105341185A (zh) | 一种复合营养调和油及其制备方法 | |
CN101040711A (zh) | 碱蓬植物提取物在制备具有减肥降脂保健食品中的应用 | |
CN104286273A (zh) | 铁皮石斛的用途及其茶叶制品 | |
CN1904023A (zh) | 一种保健葡萄饮品 | |
CN102754767A (zh) | 降血糖泥鳅面条及其制作方法 | |
KR20170013688A (ko) | 뽕잎 추출액을 함유한 양파즙 및 이의 제조방법 | |
CN100579391C (zh) | 一种养肺保健面条 | |
CN101703702A (zh) | 一种降脂减肥茶的制作方法 | |
CN105661208A (zh) | 一种具有辅助降血压功效的复合果蔬饮料 | |
CN100518541C (zh) | 一种黄耆保健面条 | |
JP2007124943A (ja) | 味噌ドリンク | |
CN105087284B (zh) | 一种复方树莓养生酒及其制备方法 | |
CN107279720A (zh) | 一种桑叶手工空心挂面及制备方法 | |
KR102238009B1 (ko) | 노니가 함유된 홍삼 가공품 및 이의 제조방법 | |
CN107223937A (zh) | 一种养胃型水煮花生米加工方法 | |
CN100370922C (zh) | 一种鱼汤及其制备方法 | |
KR20060097877A (ko) | 만성기관지염에 유효한 은행 외과피의 발효추출액 및 그 제조방법 | |
CN101889681B (zh) | 葱耳玉旨胶囊及其生产工艺 | |
KR101856427B1 (ko) | 당뇨 환자용 기능성 음료 제조 방법 | |
CN107287089A (zh) | 一种荔枝果醋及其制备方法 | |
KR20090025106A (ko) | 운지버섯 및 콜라겐을 함유하는 침출차 조성물과 그 제조방법 및 이를 이용한 액상추출차의 제조방법 | |
CN1868489A (zh) | 具有防治高血脂功能的醋 | |
CN106689832A (zh) | 一种黑木耳茶寿面及制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160615 |
|
RJ01 | Rejection of invention patent application after publication |